"instanceType","id","versionIdentifier","rationale","uuid:ID"
"StudyVersion","StudyVersion_1","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","0839226d-39de-412b-a5e1-244ee3154c12"
